10-Q: Microbot Medical Inc. Reports Third Quarter 2024 Results, Advances LIBERTY Robotic System

Microbot Medical Inc. announces its third quarter 2024 financial results, highlighting progress in its LIBERTY Endovascular Robotic Surgical System development and clinical trial.

Summary

• Microbot Medical Inc. reported a net loss of $3.215 million for the three months ended September 30, 2024, and a net loss of $8.051 million for the nine months ended September 30, 2024.
• The company's research and development expenses were $2.060 million for the quarter and $4.646 million for the nine-month period.
• General and administrative expenses totaled $1.240 million for the quarter and $3.549 million for the nine-month period.
• As of September 30, 2024, Microbot had cash and cash equivalents of $479,000 and marketable securities of $3.859 million.
• The company has raised approximately $72.8 million since inception through September 30, 2024, and has incurred a cumulative loss of approximately $87.5 million.
• Microbot has received grants from the Israeli Innovation Authority totaling approximately $1.9 million since 2013.
• The company is developing the LIBERTY Endovascular Robotic Surgical System, a fully disposable robotic system for endovascular procedures.
• Microbot received FDA approval to proceed with its pivotal human clinical trial for the LIBERTY system and has completed enrollment and follow up for all patients.
• The company anticipates filing its 510(k) submission with the FDA by the end of 2024 and receiving 510(k) clearance in the first half of 2025.
• CE Mark approval is anticipated in the second half of 2026 due to recent regulatory changes in Europe.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the company's ongoing losses, low cash balance, going concern warning, and potential delays in regulatory approvals. However, the progress in clinical trials and FDA approval provides some positive outlook.

Positives

• The company received FDA approval to proceed with its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System.
• Microbot successfully completed enrollment and follow up for all patients in its human clinical trial.
• The company anticipates filing its 510(k) submission with the FDA by the end of 2024.
• Microbot has received ISO 13485 certification for its quality management system, a requirement for CE mark approval.
• The company has completed all biocompatibility tests required by its Investigational Device Exemption (IDE) application.

Negatives

• Microbot reported a net loss of $3.215 million for the third quarter of 2024 and a net loss of $8.051 million for the nine months ended September 30, 2024.
• The company has incurred a cumulative loss of approximately $87.5 million since inception.
• Microbot's cash and cash equivalents are relatively low at $479,000 as of September 30, 2024.
• The company has not generated revenue from operations to date.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is facing potential delays in CE Mark approval due to recent regulatory changes in Europe, now anticipated in the second half of 2026.

Risks

• The company has not generated revenue from operations and has incurred significant losses since inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's ability to raise additional capital is uncertain and dependent on market conditions.
• The ongoing war in Israel could adversely affect the company's operations and ability to meet milestones.
• The company is subject to regulatory risks, including the FDA approval process and CE Mark approval.
• The company is dependent on the successful development and commercialization of its LIBERTY Endovascular Robotic Surgical System.
• The company received a deficiency letter from Nasdaq for not meeting the minimum bid price requirement, which could lead to delisting.

Future Outlook

The company anticipates filing its 510(k) submission with the FDA by the end of 2024 and receiving 510(k) clearance in the first half of 2025. CE Mark approval is anticipated in the second half of 2026. The company intends to raise capital through future public and private issuances of debt and/or equity securities, including continuing to raise capital, if available, pursuant to the ATM Agreement.

Management Comments

• Management believes the company has sufficient funds for operations for less than one year.
• Management is closely monitoring how the military operation and related activities in Israel could adversely affect its anticipated milestones.
• Management has determined that there have not been any materially adverse effects on its business or operations due to the war in Israel as of the filing date of the report.

Industry Context

Microbot Medical is operating in the competitive medical device industry, specifically in the area of robotic surgery. The company's focus on a fully disposable robotic system for endovascular procedures is a unique approach that could differentiate it from competitors. The company's progress in clinical trials and regulatory approvals is critical for its success in this market.

Comparison to Industry Standards

• Microbot's R&D spending is typical for a pre-revenue medical device company focused on innovative technology.
• The company's cash burn rate is high, which is common for companies in the development stage, but the low cash balance is a concern.
• The timeline for FDA 510(k) clearance and CE Mark approval is consistent with industry averages for novel medical devices.
• The company's reliance on equity financing is typical for early-stage medical device companies, but the potential for dilution is a risk for investors.
• Compared to established robotic surgery companies like Intuitive Surgical, Microbot is at a much earlier stage of development and commercialization.

Legal Proceedings

• The company is involved in ongoing litigation related to the 2017 financing, which was settled in January 2024.
• The company is also involved in litigation with Joseph Mona, which is currently under appeal.

Stakeholder Impact

• Shareholders are impacted by the company's ongoing losses and potential dilution from future capital raises.
• Employees are impacted by the company's financial situation and potential for future cost-cutting measures.
• Customers (potential future users of the LIBERTY system) are impacted by the company's progress in clinical trials and regulatory approvals.
• Suppliers and vendors are impacted by the company's financial stability and ability to pay for goods and services.
• Creditors are impacted by the company's going concern warning and ability to repay debts.

Next Steps

• The company anticipates filing its 510(k) submission with the FDA by the end of 2024.
• The company expects to receive 510(k) clearance from the FDA in the first half of 2025.
• The company anticipates CE Mark approval in the second half of 2026.
• The company will continue to raise capital through future public and private issuances of debt and/or equity securities.

Key Dates

Keywords

Microbot Medical, LIBERTY Endovascular Robotic Surgical System, medical devices, robotic surgery, endovascular, FDA approval, clinical trial, CE Mark, financial results, research and development